Lewis Sanders
Sanders Capital
Lewis Sanders HCA Healthcare, Inc stake
total: 128
Sanders Capital HCA trades
- Total transactions:
- 26
- New positions:
- 2
- Sold out:
- 1
- Added:
- 16
- Reduced:
- 7
- Held since:
- 2020 Q2
- Held for:
- 24 quarters
- Latest activity:
- 2026 Q1
According to 2026 Q1 report, Lewis Sanders holds 8,957,145 HCA Healthcare, Inc (HCA) shares with a market value of roughly $4.24B accounting for 5.05% of the overall portfolio. To date, the estimated cost basis is nearly $151.05 for "buy" trades and estimated average "sell" price is $412.44. Sanders Capital first purchased HCA in 2016 Q1, initially acquiring 109,400 shares. Lewis Sanders later completely sold out the position and invested in HCA Healthcare, Inc again in 2020 Q2. Since the initial investment in HCA Healthcare, Inc (HCA), Sanders Capital has made 25 more transactions.
When did Lewis Sanders buy HCA Healthcare, Inc (HCA)?
Lewis Sanders first invested in HCA Healthcare, Inc (HCA) in 2016 Q1 at the reported quarter-end price of $78.05 per share.
What's the cost basis of Sanders Capital's HCA stake?
The estimated cost basis for HCA Healthcare, Inc (HCA) stake is around $151.05 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $151.05
- Weighted AVG sell price:
- $412.44
Lewis Sanders's historical trades in HCA Healthcare, Inc
26 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
5.05%
|
8,957,145
|
$473.24
|
$4,238,879,300
|
-14.40% (-1,507,023)
|
-0.82%
|
|
2025 Q4
|
5.63%
|
10,464,168
|
$466.86
|
$4,885,301,472
|
-1.98% (-211,495)
|
-0.12%
|
|
2025 Q3
|
5.60%
|
10,675,663
|
$426.20
|
$4,549,967,571
|
-3.85% (-426,920)
|
-0.24%
|
|
2025 Q2
|
5.71%
|
11,102,583
|
$383.10
|
$4,253,399,547
|
-4.00% (-462,564)
|
-0.26%
|
|
2025 Q1
|
5.97%
|
11,565,147
|
$345.55
|
$3,996,336,546
|
-0.78% (-90,416)
|
-0.05%
|
|
2024 Q4
|
5.12%
|
11,655,563
|
$300.15
|
$3,498,417,234
|
+1.01% (+116,826)
|
+0.05%
|
|
2024 Q3
|
6.79%
|
11,538,737
|
$406.43
|
$4,689,688,879
|
+0.16% (+18,175)
|
+0.01%
|
|
2024 Q2
|
5.67%
|
11,520,562
|
$321.28
|
$3,701,326,159
|
+0.73% (+83,557)
|
+0.04%
|
|
2024 Q1
|
6.37%
|
11,437,005
|
$333.53
|
$3,814,584,278
|
+0.29% (+33,002)
|
+0.02%
|
|
2023 Q4
|
5.71%
|
11,404,003
|
$270.68
|
$3,086,835,532
|
+4.17% (+456,738)
|
+0.23%
|
|
2023 Q3
|
5.69%
|
$245.98
|
+0.07% (+7,598)
|
|||
|
2023 Q2
|
6.94%
|
$303.48
|
+3.35% (+354,323)
|
|||
|
2023 Q1
|
6.61%
|
$263.68
|
-1.44% (-154,207)
|
|||
|
2022 Q4
|
6.76%
|
$239.96
|
-3.46% (-385,192)
|
|||
|
2022 Q3
|
5.62%
|
$183.79
|
+0.04% (+4,253)
|
|||
|
2022 Q2
|
4.73%
|
$168.06
|
+14.10% (+1,374,130)
|
|||
|
2022 Q1
|
5.31%
|
$250.62
|
+3.16% (+298,323)
|
|||
|
2021 Q4
|
4.95%
|
$256.92
|
+16.90% (+1,365,582)
|
|||
|
2021 Q3
|
4.45%
|
$242.72
|
+0.25% (+20,334)
|
|||
|
2021 Q2
|
3.78%
|
$206.74
|
+3.42% (+266,566)
|
|||
|
2021 Q1
|
3.54%
|
$188.34
|
+1.59% (+121,700)
|
|||
|
2020 Q4
|
3.33%
|
$164.46
|
+7.57% (+540,322)
|
|||
|
2020 Q3
|
3.05%
|
$124.68
|
+3.78% (+259,582)
|
|||
|
2020 Q2
|
2.49%
|
$97.06
|
new
|
|||
|
2016 Q2
|
0.00%
|
$78.05
|
-100% (-109,400)
|
|||
|
2016 Q1
|
0.07%
|
$78.05
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.